Interestingly, this analysis revealed that the group of patients with glioma that have up-regulated levels of both ADAMTS1 and IGFBP2 showed a shorter survival time, with significant differences to patients with up-regulated levels of IGFBP2 (p-value=0.0352), and to patients without up-regulation of any of these genes (p-value<0.0001). The gene discussed is IGFBP2; the disease is glioma.